Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)

Reports Q2 revenue $1.8M, consensus $819,750. “In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody(TM) ISAC in our pipeline,” said Willie Quinn, president and CEO. “We are now conducting a Phase 1 dose-escalation study for patients with gastric and gastroesophageal cancer in Australia, and will expand to other countries in the second half of 2025. We look forward to presenting initial data in the first half of 2026. We also continue to seek a partner for further development of our dectin-2 agonist antibody BDC-3042, which demonstrated activity in lung cancer patients in the form of a partial response (PR) at the highest dose tested. Patients at the highest doses also had a strong immune response consistent with our expectations based on preclinical data.”